Nintedanib (Prutis): Antifibrotic Therapy for Pulmonary Fibrosis & ILDs

Prutis, containing the active ingredient Nintedanib, is a clinically proven antifibrotic therapy designed to slow the progression of lung fibrosis in patients with serious interstitial lung diseases (ILDs). These conditions, including Idiopathic Pulmonary Fibrosis (IPF), Progressive Fibrosing Interstitial Lung Disease (PF-ILD), and Systemic Sclerosis-Associated ILD (SSc-ILD), lead to irreversible scarring of the lungs, making breathing difficult and gradually reducing overall quality of life. By targeting multiple signaling pathways responsible for fibrosis, Prutis helps preserve lung function, delay disease progression, and provide patients with a better opportunity to maintain daily activities and independence.

Available in 100 mg and 150 mg softgel capsule strengths, Prutis is prescribed under medical supervision to match the specific needs of each patient. The standard recommended dose is 150 mg twice daily, approximately 12 hours apart, taken with food. For some patients, such as those with mild hepatic impairment or those who experience side effects at the higher dose, a reduced dose of 100 mg twice daily may be advised. Capsules should always be swallowed whole and never chewed or crushed.

Prutis has been extensively studied in global clinical trials, including landmark studies such as INPULSIS and INBUILD, which have shown that Nintedanib significantly slows the decline in lung function compared to untreated patients. This reduction in the rate of lung function decline can translate into meaningful improvements in a patient’s ability to perform everyday tasks, maintain physical activity, and manage symptoms. In addition, early initiation of therapy has been associated with better outcomes, emphasizing the importance of timely diagnosis and specialist consultation.

While Prutis is generally well tolerated, patients may experience side effects, most commonly gastrointestinal issues such as diarrhea, nausea, or loss of appetite. These symptoms are usually manageable under medical guidance, and dose adjustments can help improve tolerance. Regular monitoring, including liver function tests, is recommended to ensure safety throughout the course of treatment. Prutis is not recommended during pregnancy or breastfeeding, and effective contraception is advised for both men and women of reproductive potential while using the therapy.

Prutis represents a trusted treatment option for patients living with progressive ILDs. It is part of a modern approach to managing these challenging conditions, combining evidence-based clinical outcomes with practical considerations for patient care. By slowing the progression of lung fibrosis, Prutis gives patients and their families more time to focus on quality of life and daily well-being.

If you or a loved one has been diagnosed with IPF, PF-ILD, or SSc-ILD, it is important to speak with a pulmonologist or qualified healthcare provider about whether Prutis may be suitable. This website provides comprehensive information about the medication, clinical evidence, patient resources, and guidelines for safe use, helping patients and healthcare professionals make informed decisions about treatment.